These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
582 related articles for article (PubMed ID: 27905258)
1. HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin). Kako S; Akahoshi Y; Harada N; Nakano H; Kameda K; Ugai T; Yamasaki R; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Ashizawa M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kanda Y Hematology; 2017 Apr; 22(3):129-135. PubMed ID: 27905258 [TBL] [Abstract][Full Text] [Related]
2. Haploidentical transplantation using low-dose alemtuzumab: Comparison with haploidentical transplantation using low-dose thymoglobulin. Kako S; Gomyo A; Akahoshi Y; Harada N; Kameda K; Ugai T; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Sato M; Terasako-Saito K; Kimura SI; Kikuchi M; Nakasone H; Kanda J; Kanda Y Eur J Haematol; 2019 Mar; 102(3):256-264. PubMed ID: 30578673 [TBL] [Abstract][Full Text] [Related]
3. The Role of Low-dose Anti-thymocyte Globulin as Standard Prophylaxis in Mismatched and Matched Unrelated Hematopoietic Peripheral Stem Cell Transplantation for Hematologic Malignancies. Sakellari I; Batsis I; Bousiou Z; Mallouri D; Constantinou V; Gavriilaki E; Smias C; Yannaki E; Kaloyannidis P; Papaioannou G; Stavroyianni N; Syrigou A; Sotiropoulos D; Fylaktou A; Tsompanakou A; Saloum R; Anagnostopoulos A Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):658-666. PubMed ID: 28716402 [TBL] [Abstract][Full Text] [Related]
4. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies. Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687 [TBL] [Abstract][Full Text] [Related]
6. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia. Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871 [TBL] [Abstract][Full Text] [Related]
7. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. Duvic M; Donato M; Dabaja B; Richmond H; Singh L; Wei W; Acholonu S; Khouri I; Champlin R; Hosing C J Clin Oncol; 2010 May; 28(14):2365-72. PubMed ID: 20351328 [TBL] [Abstract][Full Text] [Related]
8. Comparison of ATG-thymoglobulin with ATG-Fresenius for Epstein-Barr virus infections and graft-versus-host-disease in patients with hematological malignances after haploidentical hematopoietic stem cell transplantation: a single-center experience. Zhou L; Gao ZY; Lu DP Ann Hematol; 2020 Jun; 99(6):1389-1400. PubMed ID: 32291495 [TBL] [Abstract][Full Text] [Related]
10. [The clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with haploidentical donor hematopoietic stem cell transplantation]. Fu L; Wei N; Wang JS; Wu L; Wang YN; Huang DY; Liu JL; Wang Z Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):273-278. PubMed ID: 28355720 [No Abstract] [Full Text] [Related]
11. Allogeneic hemopoietic stem cell transplantation (HSCT) for Wiskott-Aldrich syndrome: a report of the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON). Muñoz A; Olivé T; Martinez A; Bureo E; Maldonado MS; Diaz de Heredia C; Sastre A; Gonzalez-Vicent M; Pediatr Hematol Oncol; 2007 Sep; 24(6):393-402. PubMed ID: 17710656 [TBL] [Abstract][Full Text] [Related]
12. Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients. Ye P; Wu M; Cao J; Pei R; Yuan J; Zhuang H; Fang Y; Lu Y Ann Hematol; 2024 Aug; 103(8):3135-3143. PubMed ID: 38809457 [TBL] [Abstract][Full Text] [Related]
13. TcRαβ-depleted haploidentical transplantation results in adult acute leukemia patients. Kaynar L; Demir K; Turak EE; Öztürk ÇP; Zararsız G; Gönen ZB; Gökahmetoğlu S; Şıvgın S; Eser B; Köker Y; Solmaz M; Ünal A; Çetin M Hematology; 2017 Apr; 22(3):136-144. PubMed ID: 27724812 [TBL] [Abstract][Full Text] [Related]
14. Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. Finke J; Schmoor C; Lang H; Potthoff K; Bertz H J Clin Oncol; 2003 Feb; 21(3):506-13. PubMed ID: 12560442 [TBL] [Abstract][Full Text] [Related]
15. A conditioning platform based on fludarabine, busulfan, and 2 days of rabbit antithymocyte globulin results in promising results in patients undergoing allogeneic transplantation from both matched and mismatched unrelated donor. Devillier R; Fürst S; Crocchiolo R; El-Cheikh J; Castagna L; Harbi S; Granata A; D'Incan E; Coso D; Chabannon C; Picard C; Etienne A; Calmels B; Schiano JM; Lemarie C; Stoppa AM; Bouabdallah R; Vey N; Blaise D Am J Hematol; 2014 Jan; 89(1):83-7. PubMed ID: 24108528 [TBL] [Abstract][Full Text] [Related]
16. Outcomes with low dose anti-thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation. Chalchal H; Dhir V; Masurekar A; Atkins H; Bredeson C; Kennah M; Kekre N; Allan D; Vasudevan Nampoothiri R Eur J Haematol; 2024 Oct; 113(4):543-549. PubMed ID: 38979885 [TBL] [Abstract][Full Text] [Related]
17. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. Law AD; Salas MQ; Lam W; Michelis FV; Thyagu S; Kim DDH; Lipton JH; Kumar R; Messner H; Viswabandya A Biol Blood Marrow Transplant; 2018 Nov; 24(11):2259-2264. PubMed ID: 30009980 [TBL] [Abstract][Full Text] [Related]
18. Assessment of Patient-Specific Human Leukocyte Antigen Genomic Loss at Relapse After Antithymocyte Globulin-Based T-Cell-Replete Haploidentical Hematopoietic Stem Cell Transplant. Wu H; Shi J; Luo Y; Yu J; Lai X; Liu L; Fu H; Ouyang G; Xu X; Xiao H; Huang H; Zhao Y JAMA Netw Open; 2022 Apr; 5(4):e226114. PubMed ID: 35385089 [TBL] [Abstract][Full Text] [Related]
19. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Ruggeri A; Sun Y; Labopin M; Bacigalupo A; Lorentino F; Arcese W; Santarone S; Gülbas Z; Blaise D; Messina G; Ghavamzadeh A; Malard F; Bruno B; Diez-Martin JL; Koc Y; Ciceri F; Mohty M; Nagler A Haematologica; 2017 Feb; 102(2):401-410. PubMed ID: 27758821 [TBL] [Abstract][Full Text] [Related]
20. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center. Huang X; Liu D Clin Transpl; 2011; ():237-45. PubMed ID: 22755417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]